Loading…

Salvage Therapy with Bevacizumab–Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

Abstract We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25–50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease,...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2009-07, Vol.56 (1), p.207-211
Main Authors: Medioni, Jacques, Banu, Eugeniu, Helley, Dominique, Scotte, Florian, Fournier, Laure, Mejean, Arnaud, Chedid, Antoine, Azizi, Michel, Andrieu, Jean-Marie, Oudard, Stéphane
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25–50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab–sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2009.01.001